Viemed Healthcare Inc (VMD) valuation
Viemed Healthcare P/E ratio history
Viemed Healthcare trades at 26.9 times its earnings over the last twelve months and 20.2 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 10.0 (year to Dec 2020) to 47.3 (year to Dec 2022), with a median of 26.2.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $7.43 | $0.37 | 20.1 |
| Dec 31, 2024 | $8.02 | $0.28 | 28.6 |
| Dec 31, 2023 | $7.85 | $0.25 | 31.4 |
| Dec 31, 2022 | $7.56 | $0.16 | 47.3 |
| Dec 31, 2021 | $5.22 | $0.22 | 23.7 |
| Dec 31, 2020 | $7.76 | $0.78 | 10.0 |
| Dec 31, 2019 | $6.20 | $0.21 | 29.5 |
| Dec 31, 2018 | $3.80 | $0.24 | 15.8 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Viemed Healthcare valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Viemed HealthcareVMD | $371M | 26.9 | 20.2 | 1.2 |
| EmbectaEMBC | $371M | 4.3 | 3.5 | 0.4 |
| RegenxbioRGNX | $372M | — | — | 2.1 |
| Tectonic TherapeuticTECX | $373M | — | — | — |
| Capricor TherapeuticsCAPR | $369M | — | — | — |
| Orthofix MedicalOFIX | $367M | — | 23.3 | 0.4 |
| RezoluteRZLT | $380M | — | — | — |
| Strata Critical Medical Inc ClassSRTA | $384M | 8.9 | — | 1.5 |
| Fennec PharmaceuticalsFENC | $356M | — | 16.2 | 6.0 |
| Peer median | 6.6 | 16.2 | 1.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: VMD financials · VMD returns
No forecast, no recommendation. This page describes Viemed Healthcare Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.